Möchten Sie immer auf dem neuesten Stand bleiben?

Investa data shows UK retail investors sharply increased defensive put options ahead of geopolitical tensions.

Recent Phase 2 topline results demonstrate NS002’s potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study...

Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting...

ORLANDO, Fla., March 24, 2026 (GLOBE NEWSWIRE) -- Worth, the fintech platform modernizing onboarding and underwriting Small and Medium-sized Businesses (SMB) for Financial Institutions, has...

Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting...

NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer,...

Inclusion Comes Shortly After Completion of U.S. IPO WASHINGTON, March 24, 2026 (GLOBE NEWSWIRE) -- Public Policy Holding Company, Inc. (“PPHC” or “the Company”) (Nasdaq: PPHC) (AIM: PPHC.L), a...

GEVORKYAN, a.s. oznamuje úspešnú realizáciu ABB, na základe ktorej získala kapitál na ďalší rozvoj výrobných kapacít, technologické inovácie a posilnenie svojho postavenia na medzinárodných trhoch,...

GEVORKYAN, a.s. oznamuje úspěšnou realizaci ABB, na jejímž základě získala kapitál na další rozvoj výrobních kapacit, technologické inovace a posílení svého postavení na mezinárodních trzích, včetně...

GEVORKYAN, a.s. announces the successful completion of ABB, through which it obtained capital for the further development of its production capacities, technological innovation, and strengthening of...